Difference between revisions of "Moxetumomab pasudotox (Lumoxiti)"
Jump to navigation
Jump to search
m (→Also known as) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
||
| Line 16: | Line 16: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | + | ||
[[Category:Immunotoxin]] | [[Category:Immunotoxin]] | ||
[[Category:Anti-CD22 antibodies]] | [[Category:Anti-CD22 antibodies]] | ||
Revision as of 19:34, 27 February 2020
Mechanism of action
A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody covalently fused to a 38 KDa fragment of Pseudomonas exotoxin-A (PE38)
Diseases for which it is used
History of changes in FDA indication
- 9/13/2018: Initial FDA approval "for adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)."
Also known as
- Generic name: moxetumomab pasudotox-tdfk
- Code names: CAT-8015, HA22
- Brand name: Lumoxiti